ASTRAZENECA PHARMA INDIA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,222 INR | -0.49% |
|
+2.44% | +12.72% |
| Sales 2022 | 8.06B 96.49M | Sales 2023 | 10.03B 120M | Capitalization | 81.18B 972M |
|---|---|---|---|---|---|
| Net income 2022 | 616M 7.38M | Net income 2023 | 993M 11.89M | EV / Sales 2022 | 7.38 x |
| Net cash position 2022 | 4.4B 52.67M | Net cash position 2023 | 4.93B 59.06M | EV / Sales 2023 | 7.6 x |
| P/E ratio 2022 |
104
x | P/E ratio 2023 |
81.8
x | Employees | - |
| Yield 2022 |
0.39% | Yield 2023 |
0.49% | Free-Float | 12.42% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.60% | ||
| 1 week | +2.33% | ||
| Current month | +0.85% | ||
| 1 month | +18.19% | ||
| 3 months | +16.11% | ||
| 6 months | +32.21% | ||
| Current year | +12.59% |
1 week
5 415.55
6 321.00
1 month
5 180.606 729.60
Current year
4 050.157 208.00
1 year
3 463.857 208.00
3 years
2 437.757 208.00
5 years
1 635.307 208.00
10 years
785.307 208.00
| Managers | Title | Age | Since |
|---|---|---|---|
Siva Padmanabhan
CEO | Chief Executive Officer | - | - |
Sanjeev Panchal
CEO | Chief Executive Officer | - | 03-01-31 |
Bhavana Agrawal
DFI | Director of Finance/CFO | - | 23-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Revathy Ashok
BRD | Director/Board Member | 65 | 16-12-01 |
| Chairman | 67 | 12-12-05 | |
| Director/Board Member | 50 | 21-12-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 114 M€ | +4.36% | - | |
| 0.00% | 32 M€ | +4.30% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 6,222 | -0.49% | 314 |
| 24-06-07 | 6,252 | +0.76% | 868 |
| 24-06-06 | 6,205 | +3.36% | 653 |
| 24-06-05 | 6,003 | +6.62% | 814 |
| 24-06-04 | 5,631 | -7.29% | 3,200 |
Delayed Quote Bombay S.E., June 10, 2024 at 02:30 am EDT
More quotes
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Companyâs DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Sector
Pharmaceuticals
Calendar
2024-08-11
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +12.59% | 1.87B | |
| +45.82% | 765B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| -0.78% | 219B | |
| +11.88% | 216B | |
| +5.90% | 164B | |
| -0.73% | 162B |
- Stock Market
- Equities
- ASTRAZEN Stock
